- Home
- SMXT vs ARMP Comparison
SMXT vs ARMP Comparison
Compare SMXT & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMXT
- ARMP
- Stock Information
- Founded
- SMXT 2008
- ARMP N/A
- Country
- SMXT United States
- ARMP United States
- Employees
- SMXT N/A
- ARMP N/A
- Industry
- SMXT
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SMXT
- ARMP Health Care
- Exchange
- SMXT NYSE
- ARMP Nasdaq
- Market Cap
- SMXT 58.9M
- ARMP 52.1M
- IPO Year
- SMXT 2024
- ARMP N/A
- Fundamental
- Price
- SMXT $1.14
- ARMP $1.95
- Analyst Decision
- SMXT
- ARMP Strong Buy
- Analyst Count
- SMXT 0
- ARMP 1
- Target Price
- SMXT N/A
- ARMP $9.00
- AVG Volume (30 Days)
- SMXT 107.9K
- ARMP 624.1K
- Earning Date
- SMXT 05-16-2025
- ARMP 05-14-2025
- Dividend Yield
- SMXT N/A
- ARMP N/A
- EPS Growth
- SMXT N/A
- ARMP N/A
- EPS
- SMXT N/A
- ARMP N/A
- Revenue
- SMXT $24,150,276.00
- ARMP $4,699,000.00
- Revenue This Year
- SMXT N/A
- ARMP $8.43
- Revenue Next Year
- SMXT N/A
- ARMP N/A
- P/E Ratio
- SMXT N/A
- ARMP N/A
- Revenue Growth
- SMXT N/A
- ARMP 14.24
- 52 Week Low
- SMXT $0.60
- ARMP $0.90
- 52 Week High
- SMXT $7.97
- ARMP $3.42
- Technical
- Relative Strength Index (RSI)
- SMXT N/A
- ARMP 56.79
- Support Level
- SMXT N/A
- ARMP $1.74
- Resistance Level
- SMXT N/A
- ARMP $2.20
- Average True Range (ATR)
- SMXT 0.00
- ARMP 0.32
- MACD
- SMXT 0.00
- ARMP 0.04
- Stochastic Oscillator
- SMXT 0.00
- ARMP 50.32
About SMXT SOLARMAX TECHNOLOGY INC
SolarMax Technology Inc is an integrated solar and renewable energy company. It operates in two segments namely the United States and China. The United States business includes the sale and installation of photovoltaic and battery backup systems. China operations consist of operating and maintaining solar farm projects and identifying and procuring solar farm projects for resale to third parties. Some of its products are LG Solar Panels, QCELL Solar Panels, Panasonic Solar Panels, and others. The company generates a majority of its revenue from the Solar energy systems.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.